AbbVie Cost of Goods Sold 2010-2024 | ABBV
AbbVie annual/quarterly cost of goods sold history and growth rate from 2010 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
- AbbVie cost of goods sold for the quarter ending September 30, 2024 was $4.212B, a 35.05% decline year-over-year.
- AbbVie cost of goods sold for the twelve months ending September 30, 2024 was $18.212B, a 3.54% decline year-over-year.
- AbbVie annual cost of goods sold for 2023 was $20.415B, a 17.23% increase from 2022.
- AbbVie annual cost of goods sold for 2022 was $17.414B, a 0.18% decline from 2021.
- AbbVie annual cost of goods sold for 2021 was $17.446B, a 13.38% increase from 2020.
AbbVie Annual Cost of Goods Sold
(Millions of US $) |
| 2023 |
$20,415 |
| 2022 |
$17,414 |
| 2021 |
$17,446 |
| 2020 |
$15,387 |
| 2019 |
$7,439 |
| 2018 |
$7,718 |
| 2017 |
$7,042 |
| 2016 |
$5,832 |
| 2015 |
$4,500 |
| 2014 |
$4,426 |
| 2013 |
$4,581 |
| 2012 |
$4,508 |
| 2011 |
$4,639 |
| 2010 |
$4,293 |
| 2009 |
$4,056 |
AbbVie Quarterly Cost of Goods Sold
(Millions of US $) |
| 2024-09-30 |
$4,212 |
| 2024-06-30 |
$4,202 |
| 2024-03-31 |
$4,094 |
| 2023-12-31 |
$5,704 |
| 2023-09-30 |
$6,485 |
| 2023-06-30 |
$4,240 |
| 2023-03-31 |
$3,986 |
| 2022-12-31 |
$4,170 |
| 2022-09-30 |
$5,022 |
| 2022-06-30 |
$4,170 |
| 2022-03-31 |
$4,052 |
| 2021-12-31 |
$4,320 |
| 2021-09-30 |
$4,390 |
| 2021-06-30 |
$4,523 |
| 2021-03-31 |
$4,213 |
| 2020-12-31 |
$4,684 |
| 2020-09-30 |
$5,050 |
| 2020-06-30 |
$3,711 |
| 2020-03-31 |
$1,942 |
| 2019-12-31 |
$2,006 |
| 2019-09-30 |
$1,920 |
| 2019-06-30 |
$1,819 |
| 2019-03-31 |
$1,694 |
| 2018-12-31 |
$2,022 |
| 2018-09-30 |
$1,835 |
| 2018-06-30 |
$1,934 |
| 2018-03-31 |
$1,927 |
| 2017-12-31 |
$2,281 |
| 2017-09-30 |
$1,616 |
| 2017-06-30 |
$1,529 |
| 2017-03-31 |
$1,616 |
| 2016-12-31 |
$1,554 |
| 2016-09-30 |
$1,504 |
| 2016-06-30 |
$1,405 |
| 2016-03-31 |
$1,369 |
| 2015-12-31 |
$1,475 |
| 2015-09-30 |
$1,167 |
| 2015-06-30 |
$916 |
| 2015-03-31 |
$942 |
| 2014-12-31 |
$1,119 |
| 2014-09-30 |
$1,094 |
| 2014-06-30 |
$1,113 |
| 2014-03-31 |
$1,100 |
| 2013-12-31 |
$1,282 |
| 2013-09-30 |
$1,092 |
| 2013-06-30 |
$1,054 |
| 2013-03-31 |
$1,153 |
| 2012-12-31 |
$1,265 |
| 2012-09-30 |
$1,014 |
| 2012-06-30 |
$1,073 |
| 2012-03-31 |
$1,156 |
| 2011-12-31 |
$3,432 |
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
$1,207 |
| 2010-12-31 |
|
| 2009-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$352.544B |
$54.318B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
